Spyre Therapeutics, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Spyre Therapeutics is a biotechnology company developing antibody-based therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease, with a pipeline focused on next-generation biologics designed for extended dosing intervals.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Burrows Scott LChief Financial Officer | Sell | $18K | 200at $89.04 | Sep 1, 2026 |
| Turtle CameronChief Executive Officer | Sell | $732K | 8,400at $87.15 | Sep 1, 2026 |
| King-Jones HeidySee Remarks | Sell | $547K | 6,206at $88.17 | Sep 1, 2026 |
| King-Jones HeidySee Remarks | Sell | $419K | 4,845at $86.40 | Sep 1, 2026 |
| Burrows Scott LChief Financial Officer | Sell | $382K | 4,384at $87.11 | Sep 1, 2026 |
| Turtle CameronChief Executive Officer | Sell | $326K | 3,700at $88.06 | Sep 1, 2026 |
| Turtle CameronChief Executive Officer | Sell | $216K | 2,500at $86.36 | Sep 1, 2026 |
| Burrows Scott LChief Financial Officer | Sell | $177K | 2,016at $88.03 | Sep 1, 2026 |
| Burrows Scott LChief Financial Officer | Sell | $78K | 900at $86.25 | Sep 1, 2026 |
| King-Jones HeidySee Remarks | Sell | $36K | 400at $90.00 | Sep 2, 2026 |
| King-Jones HeidySee Remarks | Sell | $36K | 400at $89.38 | Sep 1, 2026 |
| Turtle CameronChief Executive Officer | Sell | $36K | 400at $89.07 | Sep 1, 2026 |
| Burrows Scott LChief Financial Officer | Sell | $1.63M | 18,232at $89.35 | Sep 2, 2026 |
| King-Jones HeidySee Remarks | Sell | $1.44M | 16,548at $87.20 | Sep 1, 2026 |
| Albers Jeffrey W.Director | Sell | $835K | 8,000at $104.38 | Aug 7, 2026 |
| Albers Jeffrey W.Director | Sell | $522K | 5,000at $104.47 | Aug 7, 2026 |
| Albers Jeffrey W.Director | Sell | $1.05M | 10,000at $104.68 | Aug 7, 2026 |
| Turtle CameronChief Executive Officer | Sell | $135K | 1,392at $96.82 | Aug 3, 2026 |
| Turtle CameronChief Executive Officer | Sell | $75K | 800at $93.97 | Aug 3, 2026 |
| Burrows Scott LChief Financial Officer | Sell | $10K | 100at $97.10 | Aug 3, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable SYRE activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.